{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:16:04Z","timestamp":1762175764054},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Non\u2010steroidal anti\u2010inflammatory drugs use may protect against development of oesophageal adenocarcinoma.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To define the consequences of non\u2010steroidal anti\u2010inflammatory drugs use in patients with Barrett's oesophagus.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Records of all Barrett's oesophagus\/oesophageal adenocarcinoma patients examined in Blackpool\u2010Wyre\u2010Fylde area were reviewed. All surviving patients completed validated questionnaires.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Use of non\u2010steroidal anti\u2010inflammatory drugs of any type and at any frequency was more prevalent in Barrett's oesophagus patients [147 (38%) Barrett's oesophagus vs. 30 (26%) oesophageal adenocarcinoma, <jats:italic>P<\/jats:italic>\u2003=\u20030.02]. Daily use of non\u2010steroidal anti\u2010inflammatory drugs was more prevalent in Barrett's oesophagus patients [88 (23%) Barrett's oesophagus vs. 14 (12%) oesophageal adenocarcinoma, <jats:italic>P<\/jats:italic>\u2003=\u20030.02], due to more prevalent consumption of non\u2010aspirin non\u2010steroidal anti\u2010inflammatory drugs [48 (13%) Barrett's oesophagus vs. four (4%) oesophageal adenocarcinoma, <jats:italic>P<\/jats:italic>\u2003=0.009]. There was no difference between the two groups in usage of either daily low\u2010dose aspirin or of occasional non\u2010steroidal anti\u2010inflammatory drugs. In logistic regression analysis any use of non\u2010steroidal anti\u2010inflammatory drugs [odds ratio (OR)\u2003=\u20030571 (95% CI: 0.359\u20130.909), <jats:italic>P<\/jats:italic>\u2003=\u20030.018] and daily use of non\u2010aspirin non\u2010steroidal anti\u2010inflammatory drugs [OR\u2003=\u20030.297 (95% CI: 0.097\u20130.911), <jats:italic>P<\/jats:italic>\u2003=\u20030.034] were significant protective factors. Non\u2010steroidal anti\u2010inflammatory drugs use did not affect the survival of oesophageal adenocarcinoma patients. Oesophageal adenocarcinoma and Barrett's oesophagus consuming non\u2010steroidal anti\u2010inflammatory drugs did not differ in upper gastrointestinal bleeding [26 (15%) non\u2010steroidal anti\u2010inflammatory drugs consumers vs. 29 (9%) non\u2010consumers, <jats:italic>P<\/jats:italic>\u2003=\u20030.08], oesophageal ulcers [31 (18%) non\u2010steroidal anti\u2010inflammatory drug consumers vs. 49 (15%) non\u2010consumers, <jats:italic>P<\/jats:italic>\u2003=\u20030.43] or stricturing [19 (11%) non\u2010steroidal anti\u2010inflammatory drug consumers vs. 41 (13%) non\u2010consumers, <jats:italic>P<\/jats:italic>\u2003=\u20030.58].<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002(i) Daily use of non\u2010steroidal anti\u2010inflammatory drugs is more prevalent in Barrett's oesophagus than oesophageal adenocarcinoma patients, because of a more prevalent use of non\u2010aspirin non\u2010steroidal anti\u2010inflammatory drugs. (ii) Use of non\u2010steroidal anti\u2010inflammatory drugs in Barrett's oesophagus patients is safe if acid suppression is adequate.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02150.x","type":"journal-article","created":{"date-parts":[[2004,12,19]],"date-time":"2004-12-19T09:55:08Z","timestamp":1103450108000},"page":"645-655","source":"Crossref","is-referenced-by-count":20,"title":["Daily use of non\u2010steroidal anti\u2010inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma"],"prefix":"10.1111","volume":"20","author":[{"given":"P.","family":"Tsibouris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Hendrickse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. E. T.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311007"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.agast960614"},{"key":"e_1_2_17_4_2","first-page":"51","article-title":"Barrett's esophagus","volume":"7","author":"Spechler S.","year":"1996","journal-title":"Semin Gastrointest Dis"},{"key":"e_1_2_17_5_2","first-page":"5575","article-title":"Aspirin and the potential role of prostaglandins in colon cancer","volume":"52","author":"Marnett LJ.","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860901)58:5<1029::AID-CNCR2820580508>3.0.CO;2-D"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50008"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I"},{"key":"e_1_2_17_9_2","first-page":"97","article-title":"Use of aspirin and other nonsteroidal anti\u2010inflammatory drugs and risk of esophageal and gastric cancer","volume":"7","author":"Farrow DC","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7250.1642"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70254-X"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010700400960"},{"key":"e_1_2_17_13_2","first-page":"2929","article-title":"Increased expression of inducible nitric oxide synthetase and cyclooxygenase in Barrett's esophagus and associated adenocarcinomas","volume":"58","author":"Wilson KT","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_17_14_2","first-page":"198","article-title":"Cycloxygenase\u20102 expression in human esophageal carcinoma","volume":"59","author":"Zimmermann KC","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32371"},{"key":"e_1_2_17_16_2","first-page":"5767","article-title":"Selective inhibition of cycloxygenase\u20102 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells","volume":"60","author":"Souza RF","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90127-2"},{"key":"e_1_2_17_18_2","first-page":"893","article-title":"The anti\u2010proliferative effect of sulnidac and sulnidac sulfide on HT\u201029 colon cancer cells: alterations in tumor suppressor and cell cycle\u2010regulatory proteins","volume":"12","author":"Goldberg Y","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200106000-00001"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1996.0023"},{"key":"e_1_2_17_21_2","first-page":"2273","article-title":"Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro\u2010transformed adenoma relative to adenoma cell lines","volume":"56","author":"Elder DJ","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200911"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62245-9"},{"key":"e_1_2_17_24_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/gut.45.2008.ii37","article-title":"Functional gastroduodenal disorders","volume":"45","author":"Talley NJ","year":"1999","journal-title":"Gut"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.66"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197608262950904"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90613-0"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007730"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7250.1642"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11568"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01277.x"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05902.x"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009213431202"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.12.1678"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33580"},{"issue":"1","key":"e_1_2_17_36_2","first-page":"S37","article-title":"Non\u2010steroidal anti\u2010inflammatory drugs and gastrointestinal bleeding","volume":"31","author":"Lanas A.","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02150.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02150.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02150.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:29:27Z","timestamp":1697232567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02150.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02150.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02150.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}